September 26, 2025

Roman Sarott shortlisted with team NeoCircuit for Cancer Grand Challenges

Roman Sarott shortlisted with team NeoCircuit for Cancer Grand Challenges

The shortlist of the Cancer Grand Challenges selection process 2025 has been announced and Roman Sarott, Research Group Leader at the Max Planck Institute for Medical Research, Heidelberg and Heilbronn, has been selected for the final stages as part of team NeoCircuit. The team tackles the challenge of developing and applying novel ways to rewire cancer cells to their disadvantage.

Member of team NeoCircuit, shortlisted for the Cancer Grand Challenges 2025: Roman Sarott, Research Group Leader at Max Planck Institute for Medical Research.
© MPI for Medical Research
  • The NeoCircuit team plans to take a new approach to rewire cancer cells by developing chemicals that can bring proteins inside a cell close together and create new protein functions to trigger cancer cells to self-destruct.
  • The team is led by Nathanael Gray from Stanford University and consists of Roman Sarott and six other co-investigators from five countries.
  • It is one of 12 on the 2025 shortlist and now competes with them for up to 20 million pound sterling each, with the aim of delivering breakthroughs that no single researcher, lab, institute or country could achieve alone. 

Tackling one of the most complex problems in cancer research

A Cancer Grand Challenge represents one of the most complex problems in cancer research, requiring scientists from different research institutions to work together in international, multidisciplinary teams to find a solution. Cancer Grand Challenges are announced and funded by the global research initiative of the same name. The initiative provides significant funding to enable innovative approaches and accelerate progress in the fight against cancer. In March 2025, it announced seven new challenges, from turning Artificial Intelligence on cancer to rewiring cancer cells. A record 227 bold submissions were received.

Facing the challenge of rewiring cancer cells

The team NeoCircuit tackles the Cancer Grand Challenge of rewiring cancer cells to their disadvantage. “Our team is seeking ways to turn the molecular causes of cancer into cancer killers, effectively tricking cancer cells into self-destructing”, explains Nathanael Gray. It aims to establish a new treatment paradigm, critically with the potential to provide durable cures to patients. 

“The challenge of reprogramming cancer cells instead of just inhibiting their growth is a perfect fit for our research program. I am delighted to be part of the fantastic NeoCircuit team and that we have made it onto the shortlist. Together with the team, I am doing everything I can to ensure that we secure the funding in New York and can use it to develop new cancer therapies.” says Roman Sarott.

Director of Cancer Grand Challenges, Dr David Scott, said: “Congratulations to the 12 finalist teams who now have the opportunity to drive the next major breakthroughs in cancer research, as part of this pioneering global initiative.”

Now 30.000 pound sterling in seed funding

Each team will now receive 30.000 pound sterling in seed funding to allow the team members to come together and develop their full research proposal and compete for up to 20 million pound sterling in funding. The funded teams will be announced in March 2026 at the Cancer Grand Challenges Summit in London. 

Our latest News

discover more
Diaper Recycling: Progress Even Among the Market Leader

Diaper Recycling: Progress Even Among the Market Leader

Used diapers account for a very large portion of our waste, and to date, no economically viable recycling process has been established. In the Encycling project, the NMI team led by Dr. Anne Zeck and Dr. Simon Straß developed an enzymatic process that was successfully applied to diapers from various manufacturers. Further research was needed […]

From microscopy to AI: Andreas von Deimling shaped modern brain tumor diagnostics in Heidelberg

From microscopy to AI: Andreas von Deimling shaped modern brain tumor diagnostics in Heidelberg

After almost 20 years, Professor Dr. Andreas von Deimling has handed over leadership of Neuropathology at Heidelberg University Hospital to Professor Dr. Dr. Felix Sahm. When Andreas von Deimling was appointed W3 Professor of Neuropathology in 2007, Heidelberg Faculty of Medicine at Heidelberg University, together with the German Cancer Research Center (DKFZ), pursued a strategic […]

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany. The new facility will bring a new generation of insulin production to one of Sanofi’s largest integrated research and manufacturing sites, […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp